Crestor's AURORA dims in dialysis patients
This article was originally published in Scrip
Executive Summary
Starting long-term dialysis patients on rosuvastatin (AstraZeneca's Crestor) therapy has no beneficial effect on their rate of cardiovascular deaths, heart attacks or stroke, despite lowering their LDL-cholesterol levels, the results of the AURORA study show.